10-Q: MaxCyte Reports Increased Losses, Revenue Decline Amid Restructuring

MaxCyte, Inc. reported a significant increase in net loss and a decrease in total revenue for the third quarter and first nine months of 2025, alongside a major workforce reduction and CFO transition.

Summary

• Net loss for the three months ended September 30, 2025, increased to $12.4 million from $11.6 million in the prior year period.
• Total revenue for the three months ended September 30, 2025, decreased by 16% to $6.8 million, down from $8.2 million in the same period last year.
• Core revenue, excluding SPL program-related revenue, decreased by 21% to $6.4 million for the three months ended September 30, 2025.
• For the nine months ended September 30, 2025, net loss widened to $35.0 million from $30.5 million in the prior year period.
• Total revenue for the nine months ended September 30, 2025, decreased by 14% to $25.7 million, compared to $29.9 million in the prior year period.
• The company implemented a workforce reduction plan on September 22, 2025, affecting approximately 34% of its global workforce, incurring $3.1 million in restructuring expenses.
• Cash and cash equivalents decreased to $13.0 million as of September 30, 2025, from $27.9 million at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $31.7 million, an increase from $19.8 million in the prior year period.
• Acquired SeQure Dx, Inc. on January 29, 2025, for a preliminary purchase price of $2.3 million, which contributed $566k in revenue and $4.4 million in net loss for the nine months ended September 30, 2025.
• Signed four new Strategic Platform License (SPL) agreements in 2025 with TG Therapeutics, Anocca AB, Adicet Bio, and Moonlight Bio.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant declines in revenue, increased net losses, substantial cash burn from operations, and a large workforce reduction. While new SPL agreements and the SeQure acquisition offer long-term potential, the immediate financial performance and operational adjustments indicate considerable challenges.

Positives

• Gross margin for the three months ended September 30, 2025, slightly increased to 77% from 76% in the prior year, primarily due to an increase in higher-margin SPL program-related revenue.
• SPL program-related revenue significantly increased by 1,663% to $423k for the three months ended September 30, 2025, compared to $24k in the prior year period.
• Successfully acquired SeQure Dx, Inc., expanding service offerings for ex-vivo and in-vivo cell and gene therapy developers.
• Entered into four new Strategic Platform License (SPL) agreements in 2025, indicating continued partnership growth.

Negatives

• Total revenue decreased by 16% for the three months and 14% for the nine months ended September 30, 2025, compared to the prior year periods.
• Core revenue declined by 21% for the three months and 4% for the nine months ended September 30, 2025, driven by decreases in instrument, PA, and license revenue.
• Net loss increased to $12.4 million for the three months and $35.0 million for the nine months ended September 30, 2025, compared to the prior year periods.
• Operating loss increased to $14.1 million for the three months and $40.7 million for the nine months ended September 30, 2025.
• Cash and cash equivalents significantly decreased to $13.0 million as of September 30, 2025, from $27.9 million at December 31, 2024.
• Net cash used in operating activities increased to $31.7 million for the nine months ended September 30, 2025, indicating higher cash burn.
• Restructuring expense of $3.1 million was incurred due to a 34% workforce reduction, reflecting efforts to streamline operations and improve cost structure.
• Interest income decreased by 31% for the three months and 28% for the nine months ended September 30, 2025, due to lower interest rates and average cash/investment balances.
• Accumulated deficit increased to $251.9 million as of September 30, 2025.

Risks

• Continued significant operating losses and expectation to incur net losses as the company invests in growth.
• Ability to achieve profitability depends on successful further development, commercialization adoption, and market acceptance of products.
• Revenue may fluctuate significantly due to the timing of product sales and licenses, the uncertain timing of partner clinical progress, and dependence on partner program decisions.
• The market for non-viral delivery is highly competitive, and new GMP-grade platforms from competitors could lead to increased price pressure and negatively impact gross margins.
• Future funding requirements are uncertain and may necessitate additional equity or debt financing, potentially diluting stockholders or imposing restrictive covenants.
• Concentration of risk with certain components obtained from a single source or limited group of suppliers.
• Customer concentration risk, with one customer accounting for 28% of Q3 2025 revenue and 51% of accounts receivable as of September 30, 2025.
• Exposure to foreign currency risk due to transactions denominated in Euros and British Pounds.
• The successful integration of the SeQure acquisition is not guaranteed and could impact expected benefits.

Future Outlook

The company expects total revenue to increase over time as customer programs advance and markets grow, leading to additional instrument, license, and processing assembly sales. Revenue from processing assembly and instrument sales to cell therapy customers is anticipated to grow as programs move into clinical development and commercialization. The company also expects to attract new customers due to growth in the cell therapy pipeline and a shift towards non-viral approaches. However, revenue may fluctuate due to the timing of sales, uncertain clinical progress, and dependence on partner decisions. The company anticipates continued substantial research and development expenses and expects general and administrative expenses to increase in absolute dollars to support anticipated business growth. Recurring sales and marketing expenses are also expected to increase in absolute dollars as commercial teams and product offerings expand.

Management Comments

• "We expect program-related revenue to continue to experience variability for some time, although we anticipate that variability may moderate as the volume of SPL partnerships and associated milestones grows and matures."
• "We expect total revenue to increase over time as our customers programs advance and our markets grow, resulting in additional instrument sales and license and PA sales and also as the percentage of our installed base that are under SPL license agreements increases."
• "We believe we are well-positioned to attract new customers who may contribute to these revenues, based on the underlying growth in the cell therapy pipeline among companies in this market, the extent to which capital is available to support such companies, and in particular the switch by some cell therapy companies away from viral to non-viral approaches."
• "We believe that our continued investment in research and development is essential to our long-term competitive position."
• "We expect to continue to incur substantial research and development expenses as we invest in research and development to support our customers, develop new uses for our existing technology, and develop improved and/or new offerings for our customers and partners."
• "We expect our recurring sales and marketing expenses to increase in absolute dollars in future periods as we expand our commercial sales, marketing and business development teams, expand our product offerings, expand our collaboration efforts, increase our presence globally, and increase marketing activities to drive awareness and adoption of our products."
• "We expect that our general and administrative expenses will increase in absolute dollars in future periods, primarily due to support anticipated growth in the business."
• "Based on our current business plan, we believe that our existing cash, cash equivalents, short-term investments and internally generated cash flows will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date these consolidated financial statements have been issued."

Industry Context

MaxCyte operates in the rapidly expanding cell therapy market, including gene-editing and immuno-oncology, as well as drug discovery and biomanufacturing. The company's Flow Electroporation technology is positioned to benefit from the underlying growth in the cell therapy pipeline and a potential industry shift from viral to non-viral delivery approaches. The acquisition of SeQure Dx, Inc. aims to strengthen its position by expanding service offerings for cell and gene therapy developers across early R&D through commercialization. The market remains highly competitive, with the potential for new GMP-grade platforms from competitors to impact pricing and gross margins.

Comparison to Industry Standards

• The company's Flow Electroporation technology is used by an SPL partner to engineer the first ex-vivo cell therapy approved by the FDA in December 2023, demonstrating a significant industry validation point.
• MaxCyte's customer base includes a majority of the top 25 pharmaceutical companies based on 2024 global revenue, indicating strong adoption among industry leaders.
• The company prices its instruments at a premium, believing in the broad benefits of its platform and the limited availability of alternative clinically-validated non-viral delivery approaches, suggesting a competitive advantage in its niche.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings, and not aware of any pending or threatened legal proceeding that would have a material adverse effect on business, financial condition, or results of operations.

Related Party Transactions

• Sold $4,000 in products and services to a customer whose Board of Directors includes a member who also serves on the company's Board of Directors during the three months ended September 30, 2025.
• Sold $24,000 in products and services to a customer whose Board of Directors includes a member who also serves on the company's Board of Directors during the nine months ended September 30, 2025.
• As of September 30, 2025, had $4,000 in accounts receivable from this related party customer.

Stakeholder Impact

• **Shareholders**: Negative impact due to increased net losses, declining revenue, significant cash burn, and potential future dilution from capital raises. The workforce reduction may signal efforts to improve efficiency but also reflects underlying challenges.
• **Employees**: Significant negative impact due to a 34% workforce reduction, leading to job losses. Remaining employees may face increased workload or uncertainty.
• **Customers**: Potential positive impact from the acquisition of SeQure Dx, Inc., which expands service offerings. However, declining core revenue might raise questions about the company's stability or ability to support existing products.
• **Suppliers**: Potential impact due to concentration risk, as the company relies on a single source or limited group of suppliers for certain components. Changes in the company's financial health could affect supplier relationships.
• **Creditors**: Increased net losses and cash burn could raise concerns, although the company believes it has sufficient liquidity for the next 12 months. Potential future debt financing could alter risk profile.

Next Steps

• Substantially complete the workforce reduction plan by November 2025.
• Continue to invest in research and development to support customers, develop new uses for existing technology, and create improved/new offerings.
• Expand commercial sales, marketing, and business development teams, product offerings, and global presence.
• Douglas Swirsky will transition from CFO effective May 31, 2026, and provide consulting services for 18 months thereafter.
• Continue to obtain information to finalize the purchase price allocation for the SeQure acquisition during the measurement period (up to one year from acquisition date).

Key Dates

Recommendation

The filing reveals a deteriorating financial picture with increased net losses, significant revenue declines in core business segments, and a substantial increase in cash used for operations. The 34% workforce reduction, while aimed at cost-cutting, signals severe operational challenges. While new SPL agreements and the SeQure acquisition offer long-term strategic potential, the immediate financial performance indicates a company struggling to achieve profitability and manage its cash burn. The current trajectory suggests further downside risk, making a 'sell' recommendation appropriate for investors seeking to mitigate exposure to a company facing significant headwinds and uncertainty.

Keywords

Cell engineering, Cell therapy, Gene therapy, Electroporation, ExPERT platform, Strategic Platform Licenses, Biotechnology, Pharmaceutical, R&D, Workforce reduction, SEC filing, 10-Q